Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average (2016 - 2026)

Ani Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $523.3 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 173.28% to $523.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $523.3 million, a 173.28% increase, with the full-year FY2025 number at $472.2 million, up 133.95% from a year prior.
  • Equity Average hit $523.3 million in Q4 2025 for Ani Pharmaceuticals, up from $252.9 million in the prior quarter.
  • Over the last five years, Equity Average for ANIP hit a ceiling of $523.3 million in Q4 2025 and a floor of -$4.6 million in Q2 2023.
  • Historically, Equity Average has averaged $133.9 million across 5 years, with a median of $145.4 million in 2021.
  • Biggest five-year swings in Equity Average: tumbled 269.01% in 2023 and later skyrocketed 9573850.0% in 2024.
  • Tracing ANIP's Equity Average over 5 years: stood at $94.1 million in 2021, then skyrocketed by 112.14% to $199.7 million in 2022, then crashed by 100.0% to $2000.0 in 2023, then skyrocketed by 9573850.0% to $191.5 million in 2024, then skyrocketed by 173.28% to $523.3 million in 2025.
  • Business Quant data shows Equity Average for ANIP at $523.3 million in Q4 2025, $252.9 million in Q3 2025, and $2000.0 in Q2 2025.